srch

Clascoterone ( cortexolone 17𝛼-propionate or CB-03-01) is a novel androgen receptor inhibitor that, under the brand name of Breezula®, is being developed by Cassiopea, an Italian pharmaceutical company. Cassiopea is not as large as the typical million-dollar pharmaceutical company because its market capitalization is about 320 million US dollars.

As a reminder, the phase II clinical trial aims to verify the pharmaceutical activity of the potential drug, i.e. its ability to produce the ...

The anti-androgen drug Breezula is now being trialed for women with pattern hair loss. Today on November 13, 2019, the pharmaceutical company Cassiopea announced that a new phase 2 trial for female androgenic alopecia is soon to be …. Continue reading. “Cassiopea Launches Trial For Female Alopecia”.

Oct 13, 2021 · If all goes well, expect the phase III clinical research to begin being organized in 2022. The first patient could start treatment by the end of 2022. Barring any further delays, the trial should wrap up by the end of 2023. With some luck, you might be able to get your hands on some Breezula as soon as 2024! Conclusion

Results were extremely positive after 12 month phase 2 trials. In a nutshell, people between a NW3 to a NW5 applied various doses of topical ...

23.03.2020 · With a full lockdown in place in Italy, it definitely will delay Breezula from starting phase 3 clinical trials and until we have a better understanding and control of COVID, I can’t speculate when Breezula will be available, and there is a good possibility that phase 3 trials will not even begin until early next year.

Mar 23, 2020 · The last update we got from Breezula was on their phase 2 completion dose ranging trial that took place in Germany last July. Results were extremely positive after 12 month phase 2 trials. In a nutshell, people between a NW3 to a NW5 applied various doses of topical Breezula and it was confirmed that the best dose for maximum hair growth was at ...

Several of our pipeline products have completed Phase II studies. We expect to continue to progress these programs through Phase III trials for approval and ...

03.05.2021 · Breezula – This androgen receptor antagonist from Cassiopea is currently the second most advanced drug in the hair growth industry. A phase 3 study was expected in 2020, but due to the unexpected events of 2020, the study was postponed and is expected to start in the first half of 2021.

The Research on this Hair Loss Treatment ... As the drug has moved through phase II clinical trials, Cassiopea has documented the so-far positive ...

13.10.2021 · If all goes well, expect the phase III clinical research to begin being organized in 2022. The first patient could start treatment by the end of 2022. Barring any further delays, the trial should wrap up by the end of 2023. With some luck, you might be able to get your hands on some Breezula as soon as 2024! Conclusion

Jul 21, 2021 · I do hope Breezula will give some updates on the status of their phase 3 trials soon, things have been awfully quiet for a while now, but I assume mostly just due to the pandemic and I do believe this will most likely be available on the market to treat AA in the next 3 or so years.

Fuck it, I’m buying some Breezula (CB) Well since phase 3 trials have proven this compound to be safe enough to use in young teenager and it’s proven to lack systemic sides, I’m ordering this stuff online and using it myself until the real deal comes out. I’m only a nw1.5 but I refuse to take finasteride or minox and I refuse to wait ...

How things can change in just a few weeks. Breezula Phase 3 trials have now been delayed till 4th quarter 2020 or 1st quarter 2021. All due to ...

Cassiopea Launches Trial For Female Alopecia The anti-androgen drug Breezula is now being trialed for women with pattern hair loss. Today on November 13, 2019, the pharmaceutical company Cassiopea announced that a new phase 2 trial for female androgenic alopecia is soon to be … Continue reading

Dec 07, 2020 · The Bottom Line on Breezula. Breezula is a new name-brand drug for clascoterone, a topical solution in development that may be used to treat androgenetic alopecia. While the clinical trials for Breezula seem promising so far, we’re still a while away from phase III trials, let alone the rigorous FDA approval process.

We've seen this pattern before with the AR antagonist drug clascoterone/Winlevi (aka Breezula in 7.5%) which has been approved by the FDA for ...

Breezula is under investigation in the United States for the treatment of androgenetic alopecia, and the safety and efficacy have not been established by the United States Food and Drug Administration (FDA). The proposed brand name for clascoterone solution 7.5% is not FDA-approved. Our first-in-class topical treatment is now FDA-approved

... several biotechs have products in late-stage clinical trials, ... and with a phase III trial planned for 2021, Breezula could become the ...

M&A transaction US derma player or capital increase (H2 2020); Start phase III trials Breezula in male alopecia (H1 2021); Phase II results Breezula in ...

21.07.2021 · I do hope Breezula will give some updates on the status of their phase 3 trials soon, things have been awfully quiet for a while now, but I assume mostly just due to the pandemic and I do believe this will most likely be available on the market to treat AA in the next 3 or so years.

Apr 17, 2019 · Breezula Phase 3 trials have now been delayed till 4th quarter 2020 or 1st quarter 2021. All due to COVID-19 (Coronavirus), which has hit Italy particularly hard. More information can be found in Cassiopea’s 2019 Annual Results presentation, which was released today. The Clascoterone female pattern hair loss Phase 2 trials are on track to ...

17.04.2019 · Breezula Phase 3 trials have now been delayed till 4th quarter 2020 or 1st quarter 2021. All due to COVID-19 (Coronavirus), which has hit Italy particularly hard. More information can be found in Cassiopea’s 2019 Annual Results presentation, which was released today.

If all goes well, expect the phase III clinical research to begin being organized in 2022. The first patient could start treatment by the end of ...

“Based on these results, we plan to meet with the FDA mid-year to discuss the planned six-month Phase III trials in men.” Harbort says the plan is to begin the Phase III program before the end of this year. Additionally, she laid out plans to begin studying the safety and effectiveness of Breezula in women.